Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Nexavar® In Combination With Chemotherapy Shown To Extend Progression-Free Survival In Patients With Advanced Breast Cancer
Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. announced that their first cooperative group-sponsored randomized Phase II trial in advanced metastatic breast cancer met its primary endpoint of progression-free survival. The study evaluated Nexavar® (sorafenib) tablets in combination with the oral chemotherapeutic, capecitabine, in patients with locally advanced or metastatic HER-2 negative breast cancer. Study findings demonstrated that the median progression-free survival was extended in patients treated with Nexavar and capecitabine compared to patients receiving capecitabine and placebo. These results were statistically significant (p-value = 0.0006). In this trial, the safety and tolerability of the combination was as expected and did not show any new or unexpected toxicities. A complete data analysis from this study is expected to be presented at an upcoming scientific meeting.
generic viagra online
Keep Summer Swimming And Stamina Events Safe
Whether having fun, staying in shape or pushing your physical capacity to the extreme, the summer is a great time to enjoy your physical health and move more. Swimming and training for or participating in a marathon or triathalon can be rewarding activities -- and can stay fun with the proper preparation and form. The American Academy of Orthopaedic Surgeons (AAOS) offers summer athletes the following safety tips.
News of the day
Breast Cancer Etiology May Vary By Subtype
Women"s reproductive and lifestyle characteristics can be linked to different invasive breast cancer subtypes. Data on 2544 breast cancer cases, presented in the open access journal Breast Cancer Research, suggests that traditional risk factors for development of the condition are associated with different kinds of tumor.
Endocrinology

Randomized Controlled Trial Shows Circumcision Does Not Reduce Male-To-Female HIV Transmission

Male circumcision does not reduce the transmission of HIV from men to their female partners, according to a Lancet study conducted in Uganda, Bloomberg reports (Sargent, 7/16). The researchers recruited 922 uncircumcised HIV-positive men between the ages of 15 and 49 for the study, who were then divided into two groups - those who were "immediately circumcised" and those for whom the procedure was "delayed for two years" Reuters reports. Researchers also followed the wives and female sex partners of the men, who all were HIV-negative (Fox, 7/16). The analysis found that "18 percent of the female partners of the circumcised men became infected with the virus compared with 12 percent of the partners of men who hadn"t undergone the procedure," Bloomberg writes (7/16). Despite studies that "suggested circumcision ò€¦ can lower the rate of male-to-female virus transmission from HIV-positive men" the researchers concluded that "[c]ircumcision of HIV-infected men didn"t reduce HIV transmission to female partners over 24 months; longer-term effects could not be assessed" (Wawer et al., Lancet, July 2009). This information was reprinted from dailyreports.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily U.S. HIV/AIDS Report, search the archives and sign up for email delivery at dailyreports.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009